HC Wainwright Cuts Earnings Estimates for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities researchers at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Pyxis Oncology in a report issued on Monday, May 19th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.36) per share for the quarter, down from their prior estimate of ($0.31). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.60) EPS.

Separately, Royal Bank of Canada restated an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Pyxis Oncology currently has an average rating of "Moderate Buy" and an average target price of $9.00.

Pyxis Oncology Stock Performance

Pyxis Oncology stock traded up $0.03 during midday trading on Wednesday, reaching $1.23. 471,961 shares of the stock were exchanged, compared to its average volume of 741,968. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.39. The firm has a market cap of $76.20 million, a PE ratio of -1.19 and a beta of 1.15. The company's fifty day moving average is $1.06 and its 200-day moving average is $1.52.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PYXS. Acadian Asset Management LLC purchased a new position in Pyxis Oncology in the 1st quarter worth approximately $81,000. 683 Capital Management LLC raised its position in shares of Pyxis Oncology by 32.5% during the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company's stock valued at $539,000 after buying an additional 135,000 shares in the last quarter. Nuveen LLC bought a new stake in shares of Pyxis Oncology during the 1st quarter worth $125,000. Pier 88 Investment Partners LLC lifted its holdings in shares of Pyxis Oncology by 296.6% during the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock worth $383,000 after acquiring an additional 292,370 shares during the last quarter. Finally, Ridgeback Capital Investments L.P. purchased a new position in Pyxis Oncology in the fourth quarter worth $560,000. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.